Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease

Rationale: Lengthy, multidrug, toxic, and low-efficacy regimens limit management of pulmonary nontuberculous mycobacterial disease. Objectives: In this phase II study, we investigated the efficacy and safety of liposomal amikacin for inhalation (LAI) in treatment-refractory pulmonary nontuberculous...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Am J Respir Crit Care Med
Asıl Yazarlar: Olivier, Kenneth N., Griffith, David E., Eagle, Gina, McGinnis, John P., Micioni, Liza, Liu, Keith, Daley, Charles L., Winthrop, Kevin L., Ruoss, Stephen, Addrizzo-Harris, Doreen J., Flume, Patrick A., Dorgan, Daniel, Salathe, Matthias, Brown-Elliott, Barbara A., Gupta, Renu, Wallace, Richard J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Thoracic Society 2017
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5363966/
https://ncbi.nlm.nih.gov/pubmed/27748623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1164/rccm.201604-0700OC
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller